Rhythm Pharmaceuticals Quarterly Balance Sheet
NASDAQ: RYTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rhythm Pharmaceuticals financial position
As of Jun 30, 2026, Rhythm Pharmaceuticals reported total assets of $437.3 million, up 17.3% from a year earlier against total liabilities of $220.0 million. Shareholders' equity stood at $103.0 million, or 23.6% of assets. The company held $65.6 million in cash and equivalents against $106.1 million of debt, a net debt position of $40.5 million.
The current ratio (current assets divided by current liabilities) was 3.45, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.03.
Summary generated from market data by MetaCap's automated system. Methodology
Rhythm Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 65.61M | 62.14M | 54.30M | 52.08M | 135.59M | 106.09M | 89.14M | 47.52M | 161.67M | 53.43M | 60.08M | 64.59M |
| Short-Term Investments | 265.28M | 278.49M | 334.65M | 363.97M | 155.44M | 208.39M | 231.43M | 250.87M | 157.46M | 147.77M | 215.76M | 234.67M |
| Receivables | 40.41M | 34.19M | 26.08M | 33.03M | 26.12M | 17.82M | 18.51M | 19.31M | 17.60M | 14.70M | 14.87M | 14.54M |
| Inventory | 30.52M | 28.65M | 25.75M | 22.11M | 18.87M | 19.32M | 18.74M | 13.89M | 11.99M | 8.51M | 8.62M | 7.76M |
| Total Current Assets | 426.56M | 430.09M | 466.92M | 494.80M | 360.68M | 369.29M | 374.20M | 340.34M | 357.37M | 235.75M | 308.27M | 329.20M |
| Property, Plant & Equipment | 103.00K | 1.06M | 1.10M | 237.00K | 297.00K | 462.00K | 632.00K | 801.00K | 973.00K | 1.15M | 1.34M | 1.54M |
| Intangible Assets | 4.89M | 5.11M | 5.32M | 5.53M | 5.75M | 5.96M | 6.17M | 6.39M | 6.60M | 6.82M | 7.03M | 7.24M |
| Total Assets | 437.27M | 442.32M | 480.20M | 506.87M | 372.73M | 386.69M | 392.27M | 363.57M | 381.85M | 258.65M | 332.75M | 354.20M |
| Accounts Payable | 16.16M | 12.30M | 13.95M | 13.63M | 15.98M | 11.91M | 12.33M | 4.89M | 4.54M | 7.55M | 4.88M | 3.84M |
| Short-Term Debt | 12.70M | 10.13M | 7.30M | 5.56M | 3.78M | 1.59M | 1.54M | — | — | — | — | — |
| Total Current Liabilities | 123.59M | 103.20M | 105.94M | 104.27M | 129.46M | 111.82M | 115.52M | 97.61M | 54.72M | 54.16M | 55.20M | 50.14M |
| Long-Term Debt | 93.40M | 98.34M | 100.89M | 103.41M | 106.01M | 107.93M | 108.27M | — | — | — | 106.14M | — |
| Total Liabilities | 219.97M | 204.70M | 210.17M | 211.19M | 239.15M | 223.60M | 227.72M | 210.88M | 202.35M | 197.07M | 162.99M | 156.72M |
| Shareholders' Equity | 102.98M | 122.91M | 139.07M | 148.82M | -11.91M | 18.95M | 21.73M | 11.21M | 39.34M | 61.58M | 169.76M | 197.47M |
| Retained Earnings | -1.46B | -1.41B | -1.35B | -1.30B | -1.25B | -1.20B | -1.16B | -1.11B | -1.07B | -1.04B | -894.74M | -853.10M |
| Total Debt | 106.10M | 108.47M | 108.18M | 108.97M | 109.79M | 109.52M | 109.81M | — | — | — | 106.14M | — |
| Net Cash (Debt) | 224.79M | 232.16M | 280.77M | 307.09M | 181.24M | 204.96M | 210.75M | 298.39M | 319.13M | 201.20M | 169.70M | 299.26M |
| Shares Outstanding | 68.82M | 68.45M | 67.21M | 66.68M | 63.91M | 63.49M | 62.39M | 61.44M | 61.10M | 60.96M | 59.43M | 59.09M |
This table shows 12 quarterly periods of Rhythm Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RYTM's reporting calendar. What is a balance sheet?